Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
belagenpumatucel L × Clear all
NCT00676507 2015-05-08

STOP

NovaRx Corporation

Phase 3 Completed
532 enrolled
Thoracic

Lung Neoplasms

NCT01279798 2011-03-01

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

NovaRx Corporation

No longer available
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01058785 2010-07-29

Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NovaRx Corporation

Phase 2 Completed
75 enrolled
Thoracic

Carcinoma, Bronchogenic, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡